RefleXion Medical, a Hayward, CA-based therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT) for all stages of cancer, closed a $125M debt facility led by Oxford Finance.
$55M is available immediately to repay the company’s existing $50M of debt. The remaining $70M of the new facility will be made available upon reaching certain regulatory and commercial milestones.
RefleXion is a privately-held company developing the first biology-guided radiotherapy system. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with sub-second latency.
The funds will support the continued commercialization of the RefleXion X1 platform and the introduction of RefleXion’s novel BgRT technology.
FinSMEs
06/07/2022